Compare AIV & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | DAWN |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 970.3M |
| IPO Year | 1994 | 2021 |
| Metric | AIV | DAWN |
|---|---|---|
| Price | $5.94 | $9.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $10.00 | ★ $26.56 |
| AVG Volume (30 Days) | 2.2M | ★ 2.9M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | ★ 47.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $210,889,000.00 | $133,672,000.00 |
| Revenue This Year | $6.96 | $15.51 |
| Revenue Next Year | N/A | $49.99 |
| P/E Ratio | $3.85 | ★ N/A |
| Revenue Growth | ★ 39.67 | 31.11 |
| 52 Week Low | $5.24 | $5.64 |
| 52 Week High | $9.29 | $13.53 |
| Indicator | AIV | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 55.39 |
| Support Level | $5.53 | $9.10 |
| Resistance Level | $5.81 | $9.59 |
| Average True Range (ATR) | 0.11 | 0.51 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 84.16 | 52.45 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.